Cereno Scientific announced that the first subject has been dosed in first-in-human, Phase I, trial of novel HDAC inhibitor CS014, being developed as an innovative therapy for thrombosis prevention. The Phase I trial CS014-001, titled "A First-in-human, Open-label Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CS014 in Healthy Volunteers After Single and Multiple Administration", is conducted in partnership with the contract research organization (CRO) Clinical Trial Consultants AB (CTC), in Uppsala, Sweden. The trial is a Phase I, open-label, FIH trial designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers.

The trial will be conducted in two parts: A single ascending dose (SAD) part (Part I) will explore safety, tolerability and PK of single ascending oral doses of CS014. A multiple ascending dose (MAD) part (Part II) will explore safety, tolerability, PK, and PD following multiple ascending doses of CS014, dosed for seven days. The Phase I trial of CS014 will include around 48 subjects and results are expected in a year's time.